Walleye Capital
NVAX icon

Walleye Capital’s Novavax NVAX Stock Holding History

Walleye Capital’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.44K Sell
300
-22,100
-99% -$200K ﹤0.01% 4229
2025
Q4 		$151K Sell
22,400
-124,800
-85% -$941K ﹤0.01% 3682
2025
Q3 		$1.28M Buy
147,200
+1,800
+1% +$14K ﹤0.01% 1907
2025
Q2 		$916K Buy
145,400
+96,400
+197% +$638K ﹤0.01% 2122
2025
Q1 		$314K Buy
49,000
+17,800
+57% +$147K ﹤0.01% 2922
2024
Q4 		$251K Buy
31,200
+10,400
+50% +$100K ﹤0.01% 3576
2024
Q3 		$263K Sell
20,800
-48,700
-70% -$629K ﹤0.01% 3809
2024
Q2 		$880K Buy
69,500
+65,300
+1,555% +$657K ﹤0.01% 2983
2024
Q1 		$20.1K Buy
+4,200
New +$19.5K ﹤0.01% 4929
2023
Q3 		– Sell
-9,500
Closed -$70.6K – 5184
2023
Q2 		$70.6K Sell
9,500
-14,100
-60% -$111K ﹤0.01% 3542
2023
Q1 		$164K Buy
23,600
+2,200
+10% +$20.2K ﹤0.01% 2621
2022
Q4 		$220K Sell
21,400
-5,000
-19% -$88.2K ﹤0.01% 1974
2022
Q3 		$480K Buy
+26,400
New +$1.14M 0.01% 1504

Other funds holding NVAX

SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Walleye Capital's NVAX Position: Q1 2026 in Review

Walleye Capital reduced its Novavax (NVAX) stake by 58% in Q1 2026, selling an estimated $468K and leaving 37,920 shares worth $309K. The position accounts for ﹤0.01% of the portfolio, ranked #3045.

Walleye Capital first reported a position in NVAX in Q1 2022 and has held it in 13 quarters since. The position peaked at $4.99M in Q2 2024. 257 funds tracked by Wall St. Rank hold NVAX as of Q1 2026.

  • Walleye Capital held 37,920 shares of Novavax worth $309K as of Q1 2026.
  • Walleye Capital sold 51,639 Novavax shares in Q1 2026, an estimated $468K.
  • Novavax made up ﹤0.01% of Walleye Capital's portfolio in Q1 2026, its #3045 holding.
  • Walleye Capital first reported a position in Novavax in Q1 2022 and has held it in 13 quarters since.
  • Walleye Capital's Novavax position peaked at $4.99M in Q2 2024.
  • 257 funds tracked by Wall St. Rank held Novavax as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.